Publications

To our list of publications from PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=israelson+a&sort=date

Bakavayev S, Stavsky A, Argueti-Ostrovsky S, Yehezkel G, Barak Z, Gitler D,  Israelson A#, and Engel S#. Blocking an epitope of misfolded SOD1 ameliorates disease phenotype in a model of amyotrophic lateral sclerosis. Brain (2023, in press). (#corresponding author)

Fleisher-Berkovich S, Ventura Y, Amoyal M, Dahan A, Feinstein V, Alfahel L, Israelson A, Bernstein N, Gorelick J and Ben-Shabat S. Therapeutic Potential of the Phytocannabinoid Cannabigerol for Multiple Sclerosis: Modulation of Microglial Activation In-Vitro and In-Vivo. Biomolecules 13, 376 (2023).

Shteinfer-Kuzmine A*, Argueti-Ostrovsky S*, Leyton-Jaimes M, Anand U, Abu-Hamad S, Zalk R, Shoshan-Barmatz V# and Israelson A#. Targeting the mitochondrial protein VDAC1 as a potential therapeutic strategy in ALS. Int. J. Mol. Sci 23, 9946 (2022).

Alfahel L*, Argueti-Ostrovsky S*, Barel S*, Ali Saleh M, Kahn J, Azoulay-Ginsburg S, Rothstein A, Ebbinghaus S, Gruzman A and Israelson A. 4-phenylbutyric acid (4-PBA) derivatives prevent SOD1 amyloid aggregation in vitro with no effect on disease progression in SOD1-ALS mice. Int. J. Mol. Sci 23, 9403 (2022).

Alaskarov A*, Barel S*, Bakavayev S, Kahn J and Israelson A. MIF homolog d-dopachrome tautomerase (D-DT/MIF-2) does not inhibit accumulation and toxicity of misfolded SOD1 Sci. Rep. 12, 9570 (2022).

Malada Edelstein Y, Solomonov Y, Hadad N, Alfahel L,  Israelson A and Levy R. Early upregulation of cytosolic Phospholipase A2α in motor neurons is induced by misfolded SOD1 in a mouse model of amyotrophic lateral sclerosis. J. Neuroinflammation 18, 274 (2021).

Argueti-Ostrovsky S*, Alfahel L*, Kahn J and Israelson A. All roads lead to Rome: Different molecular players converge to common toxic pathways in neurodegeneration. Cells 10, 2438 (2021).

Bakavayev S, Argueti S, Venkatachalam N, Yehezkel G, Stavsky A, Barak Z, Israelson A#, and Engel S#. The exposure of β6/β7-loop in Zn/Cu-superoxide dismutase (SOD1) is coupled to metal loss and is transiently reversible during misfolding. ACS Chem. Neurosci. 12, 49-62 (2021) (#corresponding author)

Leyton-Jaimes M*, Ivert P*, Han Y, Hoeber J, Zhou C, Feiler A, Pankratova S, Shoshan-Barmatz V, Israelson A#, Kozlova E#. Empty mesoporous silica particles delay disease progression and extend survival in a mouse model of ALS. Sci. Rep. 10, 20675 (2020) (#corresponding author)

Leyton-Jaimes M, Kahn J and Israelson A. AAV2/9-mediated overexpression of MIF inhibits SOD1 misfolding, delays disease onset and extends survival in mouse models of inherited ALS. Proc. Natl. Acad. Sci. USA 116, 14755-14760 (2019)

Shteinfer-Kuzmine A*, Argueti S*, Gupta R*, Shvil N, Abu-Hamad S, Gropper Y, Hoeber J, Magri A, Messina A, Kozlova E, Shoshan-Barmatz V and Israelson A. A VDAC1-derived N-terminal peptide inhibits mutant SOD1-VDAC1 interactions and toxicity in the SOD1 model of ALS. Front. Cell. Neurosci. 13, 146 (2019)

Blacher E*, Bashiardes S*, Shapiro H*, Rothschild D*, Mor U, Dori-Bachash M, Kleimeyer C, Moresi C, Harnik Y, Zur M, Zabari M, Ben-Zeev Brik R, Zmora N, Cohen Y, Bar N, Levi I, Amar N, Mehlman T, Brandis A, Biton I, Kuperman Y, Tsoory M, Shental N, Alfahel L, Harmelin A, Schwartz M, Israelson A, Arike L, Johansson M, Hansson G.C., Gotkine M, Segal E, Elinav E. Potential roles of gut microbiome commensals & associated metabolites 1 in modulation of murine Amyotrophic Lateral Sclerosis. Nature 572, 474-480 (2019)

Bakavayev S, Chetrit N, Zvagelsky T, Vyazmensky M, Israelson A, and Engel S. SOD1-derived copper catalyzes homocysteine oxidation to produce reactive oxygen species. Sci. Rep. 9, 10826 (2019)

Shvil N, Banerjee V,  Zoltsman G, Shani T, Kahn J, Abu-Hamad S, Papo N, Engel S, Bernhagen J and Israelson A. MIF inhibits the formation and toxicity of misfolded SOD1 amyloid aggregates: Implications for familial ALS. Cell Death & Disease 9,107Â (2018) 

Leyton-Jaimes M, Kahn J and Israelson A. Macrophage Migration Inhibitory Factor: A Multifaceted Cytokine Implicated in Multiple Neurological Diseases. Exp. Neurol. 301,83-91Â (2018) 

Abu-Hamad S, Kahn J, Leyton-Jaimes M, Rosenblatt J and Israelson A. Misfolded SOD1 accumulation and mitochondrial association contribute to the selective vulnerability of motor neurons in familial ALS: correlation to human disease. ACS Chem. Neurosci. 8, 2225-2234Â (2017)

Shani T, Levy M, and Israelson A. Assay to measure nucleocytoplasmic transport in real time using motor neuron-like NSC-34 cells. J. Vis. Exp. 123, e55676 (2017).

Leyton-Jaimes M*, Benaim C*, Abu-Hamad S*, Guetta A, Kahn J, Bucala R, and Israelson A. Endogenous Macrophage Migration Inhibitory Factor Reduces the Accumulation and Toxicity of Misfolded SOD1 in a Mouse Model of ALS. Proc. Natl. Acad. Sci. USA 113, 10198-10203 (2016) 

Banerjee V*, Shani T, Katzman B, Vyazmensky M, Papo N, Israelson A and Engel S. SOD1 derived peptide inhibits amyloid-like aggregation of misfolded SOD1. ACS Chem. Neurosci. 7, 1595-1606 (2016)

Abu-Hamad S and Israelson A. Macrophage Migration Inhibitory Factor as a Component of Selective Vulnerability of Motor Neurons in ALS. Rare Diseases 3:1 (2015) 

Israelson A#, Ditsworth D, Sun S, Song SW, Liang J, Hruska-Plochan M, McAlonis-Downes M, Abu-Hamad S, Zoltsman G, Shani T, Maldonado M, Bui A, Navarro M, Zhou H, Marsala M, Kaspar BK, Da Cruz S and Cleveland DW#. Macrophage Migration Inhibitory Factor as a Chaperone Inhibiting Accumulation of Misfolded SOD1. Neuron 86, 218-232 (2015)  (# corresponding author)

Comments on this article:
Highlighted in Neuron with a preview article
Recommended by Faculty of 1000

Getter T, Zaks I, Barhum Y, Ben-Zur T, Bselt S, Gregoire S, Viskind O, Shani T, Gottlieb H, Green O, Shubely M, Senderowitz H, Israelson A, Kwon I, Petri S, Offen D and Gruzman A. A novel chemical chaperone-based drug candidate is effective in mouse model of amyotrophic lateral sclerosis (ALS). ChemMedChem. 10, 850-861 (2015)

Agam G and Israelson A.Why lithium studies for ALS treatment should not be halted prematurely. Front. Neurosci. 8,267 (2014)

Ben-Hail D*, Lemelson D*, Israelson A, and Shoshan-Barmatz V.  New Fluorescent Reagents Specific for Ca2+-Binding Proteins. Biochem.  Biophys. Res. Comm. 426, 158-164 (2012)

Li Q*, Vande Velde C*, Israelson A, Xie J, Bailey AO, Dong M, Chun S, Roy T, Yates JR., Capaldi RA, Cleveland DW and Miller TM. ALS-linked mutant superoxide dismutase 1(SOD1) alters mitochondrial protein composition and decreases protein import. PNAS 107, 21146-21151 (2010)

Israelson A, Arbel N, Da Cruz S, Ilieva H, Yamanaka K, Shoshan-Barmatz V and Cleveland DW. Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS. Neuron  67, 575-587 (2010)

Comments on this article:

i.Highlighted in Neuron with a preview article
ii.Featured in Nature as Research Highlights
iii.Featured in Nature Medicine as Research Highlights
iv.Recommended by Faculty of 1000

Abu-Hamad S*, Arbel N*, Calo D, Arzoine L, Israelson A, Keinan N, Ben Romano R, Friedman O and Shoshan-Barmatz V. The VDAC1 N-terminal is essential for apoptosis and regulation by anti-apoptotic  proteins.  J. Cell Sci. 122, 1906-1916 (2009)

Goldin N, Arzoine L, Heyfets A, Israelson A, Zaslavsky Z, Bravman T, Bronner V, Notcovich A, Shoshan-Barmatz V and Flescher E.  Methyl jasmonate binds to and detaches mitochondria-bound hexokinase. Oncogene  27, 4636-4643 (2008)

Abu-Hamad S*, Zaid H*, Israelson A*, Nahon E, and Shoshan-Barmatz V.  Hexokinase-I protection against apoptotic cell death is mediated via interaction with the voltage-dependent anion channel-1: mapping the site of binding. J. Biol. Chem.  283, 13482-13490 (2008)

Israelson A*, Zaid H*, Abu-Hamad S*, Nahon E and Shoshan-Barmatz V. Mapping the ruthenium red-binding site of the voltage-dependent anion channel. Cell Calcium  43, 196-204 (2008)

Israelson A, Abu-Hamad S, Zaid H, Nahon E and Shoshan-Barmatz V. Localization of the Voltage-Dependent Anion Channel-1 Ca2+-binding sites.  Cell Calcium  41, 235-244 (2007)

Israelson A, Zilberberg N and Shoshan-Barmatz V. Azido Ruthenium: A new photoreactive probe for calcium binding proteins.  Nature Protocols 1, 111-117 (2006)

Shoshan-Barmatz V, Israelson A, Brdiczka D and Sheu SS.  The voltage-dependent anion channel (VDAC): Function in intracellular signaling, cell life and cell death. Curr. Pharm. Design  12, 2249-2270 (2006)

Nahon E, Israelson A, Abu-Hamad S and Shoshan-Barmatz V. Fluoxetine (Prozac) interaction with the mitochondrial Voltage-Dependent Anion Channel and protection against apoptotic cell death.  FEBS Letters  579, 5105-5110 (2005)

Shoshan-Barmatz V and Israelson AThe voltage-dependent anion channel in endoplasmic/sarcoplasmic reticulum: Characterization, modulation and possible function. J. Membr. Biol. 204, 57-66 (2005)

Israelson A, Arzoine L, Abu-Hamad S, Khodorkobsky V, Shoshan-Barmatz V.  A Photoactivable Probe for Calcium Binding Proteins. Chem. Biol.  12, 1169-1178 (2005)

i.  Featured in Nature Chem. Biol. as Research Highlights

Zaid H*, Abu-Hamad S*, Israelson A, Nathan I and Shoshan-Barmatz V.  Voltage-dependent anion channel modulates apoptotic cell death.  Cell Death Differ. 12, 751-760 (2005)

Zalk R, Israelson A, Garty E, Azoulay-Zohar H and Shoshan-Barmatz V.  Oligomeric states of the voltage-dependent anion channel and cytochrome c release from mitochondria. Biochem. J. 386, 78-83 (2005)

Azoulay-Zohar H, Israelson A, Abu-Hamad S and Shoshan-Barmatz V. In self-defense: Hexokinase promotes VDAC closure and prevents mitochondria-mediated apoptotic cell death.  Biochem. J. 377, 347-355 (2004)

Google Scholar: https://scholar.google.com/citations?user=5MgUJ90AAAAJ&hl=en

PATENTS

1. Israelson A and Cleveland DW. Mif for use in methods of treating subjects with a neurodegenerative disorder. Publication number: WO2013184209 A1

(International Application Number PCT/US2013/031449) (2013).

2. Shoshan-Barmatz V, Israelson A and Lemelson D. Fluorescent Ruthenium Compounds for Detecting Calcium Binding Proteins.

(International Application Number PCT/IL2007/001210) (2007).

3. Shoshan-Barmatz V and Israelson A. Photoreactive Compound Specifically Binding to Calcium Binding Proteins.

(International Application Number PCT/IL2005/000203) (2005).

4- Shoshan-Barmatz V and Israelson A. VDAC1-derived N-terminal peptides and use thereof for treating ALS. (International Application PCT) (2019).

5- Kozlova E, Feiler A, Zhou C, Israelson A and Shoshan-Barmatz V. Porous particles for use in treatment, prevention and/or postponement of degeneration of neurons and glia. (International Application PCT) (2019).